<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02140229</url>
  </required_header>
  <id_info>
    <org_study_id>P130401</org_study_id>
    <nct_id>NCT02140229</nct_id>
  </id_info>
  <brief_title>Is Ultrasound Remission a Real Remission? Does Ultrasound Permit to Achieve and Maintain the Remission in Rheumatoid Arthritis Patients More Efficiently Than Clinical Scores?</brief_title>
  <acronym>REVECHO</acronym>
  <official_title>REVECHO Study (REmission Véritable en ECHOgraphie) Is Ultrasound Remission a Real Remission? Does Ultrasound Permit to Achieve and Maintain the Remission in Rheumatoid Arthritis Patients More Efficiently Than Clinical Scores?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Remission is nowadays an achievable objective for Rheumatoid Arthritis (RA) patients thanks&#xD;
      to a large choice of therapies, early treatment and tight control (30% relapse).&#xD;
&#xD;
      Ultrasound (US) driven-therapy, complemented with a clinico-biological follow-up, may improve&#xD;
      the prognosis of RA in remission by increasing the duration of sustained remission and by&#xD;
      preventing radiographic structural progression.&#xD;
&#xD;
      The tested hypothesis is: The US coverage of RA allows to increase the duration of sustained&#xD;
      clinical remission.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      REVECHO is an international prospective multicentre simple blinded randomized study with a&#xD;
      longitudinal follow-up of 18 months and a total study duration of 48 months. During the first&#xD;
      visit, after having signed the consent form, Patients undergo at each visit, a clinical&#xD;
      evaluation comprising an assessment of tender joint count (TJC), of swollen joint count&#xD;
      (SJC), pain assessment, patient global assessment of the activity of disease, as well as a&#xD;
      physician global assessment of the disease activity, an ultrasound examination of small and&#xD;
      large joints by an independent physician blinded to the clinical data, and to the results of&#xD;
      biological exams (blood sampling to assess CRP, complete blood count (CBS), and renal and&#xD;
      hepatic functions). The clinical, biological and ultrasound assessments will be performed&#xD;
      every 3 months.&#xD;
&#xD;
      Patients will be then randomly assigned to one of the 3 groups: 1) &quot;Usual care group&quot;, 2)&#xD;
      &quot;Clinical (DAS28)-ultrasound follow-up group&quot; (ultrasound-driven therapy) or 3)&#xD;
      &quot;DAS28-ACR/EULAR remission criteria group&quot; (ACR/EULAR remission criteria-driven therapy),&#xD;
      with a follow-up of 18 months.&#xD;
&#xD;
      Therapeutic decisions are taken by the Referring Rheumatologist. He/she will have DAS28 + US&#xD;
      results in the group US follow-up or DAS28 + ACR/EULAR remission criteria results in the&#xD;
      group ACR/EULAR follow-up. Therapeutic recommendations (therapeutic options, according to the&#xD;
      randomization group, a threshold of activity will be decided by a scientific committee for&#xD;
      increasing, stop or change therapy) will be given according to the group of randomization and&#xD;
      based on the level of inflammation. The Referring Rheumatologist, will be free to follow or&#xD;
      not the therapeutic advices.&#xD;
&#xD;
      In &quot;Usual care&quot; group, DAS28 and PDUS assessment will be performed at each time point,&#xD;
      however, no suggestion neither DAS28 nor PDUS results will be given to the Referring&#xD;
      Rheumatologist. The Referring Rheumatologist will be free to manage the patient as he/she&#xD;
      thinks more appropriate.&#xD;
&#xD;
      Conventional radiography (hand and feet) will be performed at baseline and at M18 follow-up.&#xD;
&#xD;
      Centralized evaluation of radiographs will be performed by 2 independent readers, using SvH&#xD;
      score. Radiographic progression will be defined by a change of SvH score between baseline and&#xD;
      M18 &gt;0.&#xD;
&#xD;
      PDUS examination will be performed every 3 months by an independent Physician in each centre,&#xD;
      blinded to clinical, biological and radiographic data. Shoulders, elbows, wrists, MCP 1 to 5,&#xD;
      PIP 1 to 5, knees, ankles (tibia-talar) and MTP 1 to 5 will be examined in B mode and in&#xD;
      Power Doppler mode.&#xD;
&#xD;
      Each joint will be scored for synovitis according to the OMERACT definition and to the&#xD;
      OMERACT scoring system (semi-quantitative score from 0 to 3 for grey scale, PD and for&#xD;
      combined score).&#xD;
&#xD;
      Questionnaire (RAPID and HAQ) scores will be also evaluated every 3 months in each group.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to loss of remission, as clinically defined by a DAS28 score ≥2.6</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>The DAS28 (Disease Activity Score for Rheumatoid Arthritis) score is calculated on the basis of swollen joint count (SJC) and tender joint count (TJC) out of 28 (shoulder, elbow, wrist, metacarpophalangeal (MCP) I-V, proximal interphalangeal (PIP) I-V, and knee) as follows:&#xD;
DAS28-CRP= 0.56 x √TJC + 0.28 x √SJC + 0.36 x Ln (CRP + 1) + 0.014 x GA + 0.96&#xD;
As a result, the DAS28 index gives a value between 0 and 10, with:&#xD;
&gt;5.1 indicating high disease activity&#xD;
3.2-5.1 indicating moderate disease activity&#xD;
&lt;3.2 indicating low disease activity&#xD;
&lt;2.6 complete remission</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of RA patients in clinical remission (DAS28 &lt;2.6) at 18 months</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of RA patients without radiographic structural progression</measure>
    <time_frame>18 months</time_frame>
    <description>Percentage of RA patients without radiographic structural progression (delta-Van der Heijde modified Sharp score ≤0) at 18 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the RAPID score and HAQ</measure>
    <time_frame>18 months</time_frame>
    <description>Evolution of the RAPID (Routine Assessment of Patient Index Data score) and HAQ (Health Assessment Questionnaire).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Remission</condition>
  <arm_group>
    <arm_group_label>Usual care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual care and follow-up every 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>US-driven therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clinical evaluation according to DAS28 + US every 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACR/EULAR remission criteria-driven therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clinical evaluation according to DAS28 + ACR/EULAR remission criteria every 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>US power doppler</intervention_name>
    <description>Clinical evaluation according to DAS28 and US every 3 months. US examination is realized in B and Doppler power mode for each studied joint: Ankles, shoulders, elbows, wrists, MCP 1 to 5, PIP 1 to 5, knees and MTP 1 to 5.</description>
    <arm_group_label>US-driven therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual care</intervention_name>
    <description>Clinical evaluation and follow-up according to the practice of the referring rheumatologist every 3 months</description>
    <arm_group_label>Usual care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ACR/EULAR criteria</intervention_name>
    <description>Evaluation based on clinical evaluation according to DAS28 and ACR/EULAR remission criteria every 3 months.</description>
    <arm_group_label>ACR/EULAR remission criteria-driven therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. RA patients (ACR 2010 criteria)&#xD;
&#xD;
          2. Disease duration ≤12 years&#xD;
&#xD;
          3. Patients of both genders above 18 years old&#xD;
&#xD;
          4. Remission according to DAS28 criteria (DAS28&lt;2.6) since at least 3 months&#xD;
&#xD;
          5. Treated with DMARDS and/or biologics with stable posology since at least 3 months&#xD;
&#xD;
          6. Treated with corticosteroids ≤5 mg/day (oral, local intra-articular or perfusion)&#xD;
             since at least 3 months&#xD;
&#xD;
          7. Affiliated to a regimen of health insurance (only for French sites)&#xD;
&#xD;
          8. Having signed a consent form&#xD;
&#xD;
          9. The patient is considered reliable, willing and capable of adhering to the protocol&#xD;
             (for example, able to understand and complete diaries), visit schedule, and medication&#xD;
             intake according to the judgment of the Investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant women&#xD;
&#xD;
          2. Predictable difficulties of follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria-Antonietta D'AGOSTINO, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rheumatology Department, Ambroise Paré Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria-Antonietta D'AGOSTINO, MD, PhD</last_name>
    <phone>+ 33 1 49 09 56 74</phone>
    <email>maria-antonietta.dagostino@apr.aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Frédérique GANDJBAKHCH, MD, PhD</last_name>
    <phone>+ 33 1 42 17 76 10</phone>
    <email>frederique.gandjbakhch@psl.aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rheumatology Department, Ambroise Paré Hospital</name>
      <address>
        <city>Boulogne</city>
        <state>Hauts DE Seine</state>
        <zip>92104</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>May 7, 2014</study_first_submitted>
  <study_first_submitted_qc>May 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2014</study_first_posted>
  <last_update_submitted>November 17, 2017</last_update_submitted>
  <last_update_submitted_qc>November 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Remission,</keyword>
  <keyword>DAS28,</keyword>
  <keyword>ACR/EULAR,</keyword>
  <keyword>RAPID, Randomized study,</keyword>
  <keyword>Longitudinal follow-up</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

